Diabetic kidney disease (DKD) is one of the most common microvascular complications of type 2 diabetes mellitus (T2DM), affecting up to 40% of diabetic patients and accounting for the leading cause of end-stage renal disease worldwide [1]. The progression of DKD involves multiple mechanisms, including oxidative stress, endothelial dysfunction, and most importantly, chronic inflammation [2].

Systemic inflammation plays a central role in renal injury by promoting glomerular and tubulointerstitial damage. the neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII) has emerged as a readily accessible markers of subclinical inflammation. Elevated NLR and SII levels have been significantly associated with increased urinary albumin excretion and decreased estimated glomerular filtration rate (eGFR) in T2DM patients [3]. It was demonstrated that patients in the highest NLR tertile had a higher prevalence of DKD, independent of confounders [4].

High-sensitivity C-reactive protein (hsCRP), is widely used to evaluate systemic inflammation. Recent studies have shown a strong association between elevated hsCRP levels and DKD development [5].Some studies provided genetic evidence supporting a causal relationship between higher hsCRP and diabetic nephropathy [6].

Monocyte chemoattractant protein-1 (MCP-1) is a chemokine involved in monocyte recruitment to inflamed renal tissues. Elevated serum and urinary MCP-1 levels have been found to predict microalbuminuria and eGFR decline in T2DM patients [7,8].

Identifying these markers may help in early diagnosis, risk stratification, and monitoring progression of DKD.

Inclusion Criteria:

• Adult aged 18-80 years, both genders.
• clear history of T2DM

Exclusion Criteria:

• Kidney disease caused by any other causes
• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 - m2
• Existing obvious infection
• Acute stage of cardiovascular or cerebrovascular diseases
• Acute complications of diabetes recently (such as diabetic ketoacidosis, et al.)
• Associated malignant tumors
• Hematological system, and autoimmune system diseases

Adult aged 18-80 years, both genders with clear history of T2DM